HCW Biologics Inc.
HCWB
$2.46
-$0.05-1.99%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 6.72M | 6.59M | 54.30K | 422.10K | 832.90K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 6.72M | 6.59M | 54.30K | 422.10K | 832.90K |
| Cost of Revenue | 274.70K | 50.40K | 43.40K | 337.60K | 666.20K |
| Gross Profit | 6.45M | 6.54M | 10.80K | 84.40K | 166.60K |
| SG&A Expenses | 9.35M | 9.71M | 10.36M | 8.90M | 9.59M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 198.10K | 198.10K | -- | -- | -- |
| Total Operating Expenses | 14.91M | 15.07M | 15.74M | 14.29M | 15.09M |
| Operating Income | -8.18M | -8.48M | -15.68M | -13.87M | -14.26M |
| Income Before Tax | -5.25M | -1.96M | -7.96M | -12.05M | -11.40M |
| Income Tax Expenses | 330.20K | 330.20K | -- | -- | -- |
| Earnings from Continuing Operations | -5.58 | -2.29 | -7.96 | -12.05 | -11.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.58M | -2.29M | -7.96M | -12.05M | -11.40M |
| EBIT | -8.18M | -8.48M | -15.68M | -13.87M | -14.26M |
| EBITDA | -7.58M | -7.72M | -14.64M | -12.30M | -12.74M |
| EPS Basic | -27.62 | -56.76 | -70.76 | -83.75 | -96.42 |
| Normalized Basic EPS | -11.82 | -16.88 | -33.60 | -39.75 | -49.27 |
| EPS Diluted | -27.62 | -56.76 | -70.76 | -83.75 | -96.42 |
| Normalized Diluted EPS | -11.82 | -16.88 | -33.60 | -39.75 | -49.27 |
| Average Basic Shares Outstanding | 3.17M | 2.14M | 1.42M | 1.04M | 816.70K |
| Average Diluted Shares Outstanding | 3.17M | 2.14M | 1.42M | 1.04M | 816.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |